CClinicalTrials.gg
Active, not recruitingNCT05532241ORTHOBIOFILMUpdated Jan 30, 2026

Dental Biofilm Control During Orthodontic Treatment

A Phase 3 interventional study of fixed metal orthodontic appliance and fixed non-metal orthodontic appliance in Gingivitis and Malocclusion, sponsored by University of Rijeka. Active, not recruiting at 3 sites in Croatia. Open to participants aged 13 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-30.

Sponsored by University of Rijeka · Phase 3, Interventional, and Supportive care

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Nov 2021, registered May 2022).
Phase
Phase 3
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
13 Years to 18 Years
Sex
All
01

Study summary

Orthodontic appliances can affect changes in the relationships of members of the oral microbiome. Microbiome imbalance can result in oral infections and complicate treatment. The focus is on the microbiological profile of dental biofilm and its control. The effects of metals released by corrosion of alloys for oral use on the microbiome and the extent to which they modify the effectiveness of gingivitis therapy by mechanical and chemical control of biofilm will be investigated. Early and late colonizers of the tooth surface will be analyzed. The condition of gingiva will be assessed, and the results will show the specifics of biofilm and gingiva exposed and unexposed, and differences in the response of individual bacteria to therapy. Molecular biology techniques will be used to quantify the total bacterial biomass (16s rRNA) and the proportion of specific bacterial species within the dental biofilm.

Read the detailed description

The aim is:

  • to determine the clinical characteristics of gingiva of subjects not exposed to metals of dental alloys and exposed to metals
  • characterization of microbiome of dental biofilm in subjects not exposed to metals of dental alloys and exposed to metals and to determine changes in the structure of dental biofilm due to exposure to metals
  • examine the extent to which environmental influences modify the effectiveness of treatment of gingivitis by mechanical removal of biofilm and chemical control (chlorhexidine digluconate mouthwash (CHX))
  • to examine the behavior of bacteria of early and late colonizers of dental biofilm after chemical control
  • to analyze biofilm on metal and non-metal appliance
  • to explore patient reported outcome measures Study design is a randomized controlled trial with 4 parallel groups: (I) fixed metal orthodontic appliance with regular oral hygiene, (II) fixed metal orthodontic appliance with CHX, (III) non-metal fixed orthodontic appliance with regular oral hygiene, and (IV) non-metal orthodontic appliance with CHX.
02

Conditions studied

  • Gingivitis
  • Malocclusion

Keywords

  • malocclusion
  • gingivitis
  • dental biofilm
03

In context

Gingivitis

590 studies on the registry are indexed under Gingivitis; 104 are open to participants now.

This study's planned enrollment of 80 is above the median of 64 across 478 interventional studies indexed under Gingivitis.

Browse Gingivitis studies →

Lead sponsor

University of Rijeka is the lead sponsor of 20 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
13 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • malocclusion with moderate or great need for orthodontic treatment (Index of Orthodontic Treatment Need grades >=3)

Exclusion criteria

Exclusion Criteria:

  • neurodevelopmental disorders
  • intellectual disability
  • oligodontia
  • congenital craniofacial anomalies
  • orofacial clefts
05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    metal + OH

    fixed metal orthodontic appliance with regular oral hygiene (toothbrush + toothpaste with low concentration of fluorides 1450 ppm)

    Device: fixed metal orthodontic appliance · Procedure: oral hygiene

  • Experimental
    metal + CHX

    fixed metal orthodontic appliance with antiseptic mouthwash one-month use (0.12% chlorhexidine digluconate)

    Device: fixed metal orthodontic appliance · Drug: Chlorhexidine mouthwash

  • Placebo comparator
    non-metal + OH

    fixed non-metal orthodontic appliance (ceramic brackets + nylon thread) with regular oral hygiene (toothbrush + toothpaste with low concentration of fluorides 1450 ppm)

    Device: fixed non-metal orthodontic appliance · Procedure: oral hygiene

  • Active comparator
    non-metal + CHX

    fixed non-metal orthodontic appliance (ceramic brackets + nylon thread) with antiseptic mouthwash one-month use (0.12% chlorhexidine digluconate)

    Device: fixed non-metal orthodontic appliance · Drug: Chlorhexidine mouthwash

Interventions

  • Devicefixed metal orthodontic appliance

    fixed metal orthodontic appliance (stainless steel brackets (Mini Master MBT 0.022'', American Orthodontics), nickel-titanium archwire (NiTi, American Orthodontics), elastomeric ligatures (Elastomerics, American Orthodontics))

    Also known as: Mini Master MBT 0.022'' and nickel-titanium archwire (American Orthodontics)

  • Devicefixed non-metal orthodontic appliance

    fixed non-metal orthodontic appliance (ceramic brackets (Radiance MBT 0.022'', American Orthodontics), polyamide thread, elastomeric ligatures (Elastomerics, American Orthodontics))

    Also known as: Radiance MBT 0.022'' (American Orthodontics) and polyamide thread

  • Procedureoral hygiene

    conducting regular oral hygiene, commonly recommended for orthodontic patients (toothbrush + toothpaste with a low fluoride concentration of 1450 ppm (Parodontax, GSK)

    Also known as: Parodontax (GSK)

  • DrugChlorhexidine mouthwash

    conducting regular oral hygiene (Parodontay, GSK) + 0.12% chlorhexidine digluconate mouthwash (Curasept ADS 212, Curaden) daily during one month

    Also known as: Parodontax (GSK) + Curasept ADS 212 (Curadent)

06

What researchers measure

Primary outcomes

  1. bacterial composition of dental biofilm

    bacterial ratio in dental biofilm (molecular biology analysis)

    Time frame: 90 days (change from start to 2 months and 3 months after start)

  2. gingival enlargement

    Seymour index (thickness (scale 0=normal-2=thickening \>=3mm) + proportion of tooth crown coverage (scale 0=normal-3=papilla involving .2/3 of adjacent tooth crown half) on frontal teeth vestibular and oral in both jaws; scale 0-100), higher score means worse outcome

    Time frame: 90 days (change from start to 2 months and 3 months after start)

Secondary outcomes

  1. dental biofilm accumulation

    Silness-Loe index and Williams modification for subjects in orthodontic treatment on a scale from 0=no biofilm to 3=a continuous line greater than 1mm, mean value of referent teeth, range 0-3, higher score indicates worse outcome

    Time frame: 90 days (change from start to 2 months and 3 months after start)

  2. pH of biofilm

    colorimetric test with pH scale in range 4-7, lower score means worse outcome (higher acidity)

    Time frame: 90 days (change from start to 2 months and 3 months after start)

  3. extent of gingivitis

    Full mouth bleeding score on a scale 0-100%, higher score means worse outcome

    Time frame: 90 days (change from start to 2 months and 3 months after start)

  4. oral health-related quality of life

    Oral Health Impact Profile (modification for gingivitis), 8 items, each on a scale 0=never-4=very often, range 0-32, higher score means worse outcome

    Time frame: 90 days (change from start to 2 months and 3 months after start)

07

Study locations

3 sites
  • University of Rijeka Faculty of Dental Medicine
    Rijeka, 51000, Croatia
  • University of Rijeka, Faculty od Dental Medicine, Dental Clinic
    Rijeka, 51000, Croatia
  • University of Rijeka, Faculty of Dental Medicine
    Rijeka, 51000, Croatia
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data will be shared on reasonable request.

Supporting information: Study protocol, Sap, Icf

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05532241
Lead sponsor
University of Rijeka
Collaborators
University of Ljubljana
Responsible party
Stjepan Spalj (Professor, University of Rijeka) — Principal investigator
First posted
Sep 8, 2022
Start date
Nov 1, 2021
Primary completion
May 1, 2025
Completion
Jun 1, 2026 (estimated)
Last update
Jan 30, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion